Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
8.69
+0.19 (2.24%)
Jun 9, 2026, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 228 employees as of December 31, 2025. The number of employees decreased by 51 or -18.28% compared to the previous year.
Employees
228
Change (1Y)
-51
Growth (1Y)
-18.28%
Revenue / Employee
$662,798
Profits / Employee
-$855,127
Market Cap
195.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 228 | -51 | -18.28% |
| Dec 31, 2024 | 279 | -46 | -14.15% |
| Dec 31, 2023 | 325 | -60 | -15.58% |
| Dec 31, 2022 | 385 | -57 | -12.90% |
| Dec 31, 2021 | 442 | 10 | 2.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 141 |
| Arcturus Therapeutics Holdings | 111 |
| Keros Therapeutics | 87 |
| Compugen | 75 |
| Cybin | 50 |
| Camp4 Therapeutics | 48 |
| ALX Oncology Holdings | 43 |
| Whitehawk Therapeutics | 23 |
KPTI News
- 6 days ago - Karyopharm Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - PRNewsWire
- 7 days ago - Karyopharm Therapeutics Transcript: Study result - Transcripts
- 7 days ago - Karyopharm Therapeutics Press release: Study result - Filings
- 7 days ago - Karyopharm Therapeutics Slides: Study result - Filings
- 7 days ago - Karyopharm says Phase 3 SENTRY trial selected for presentation at EHA 2026 - TheFly
- 7 days ago - Karyopharm’s selinexor combination shows efficacy in myelofibrosis - TheFly
- 7 days ago - Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - PRNewsWire